Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.semerg.2019.10.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.
Dermatol Ther (Heidelb)
December 2024
Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany.
Introduction: Psoriasis in high-impact areas, including the scalp, nails, palms, and soles, can disproportionately impair patient quality of life. Here, we evaluate the 2-year efficacy of bimekizumab treatment in patients with moderate to severe plaque psoriasis in post hoc analyses of five phase 3/3b trials.
Methods: High-impact area efficacy data were pooled through 2 years across five phase 3/3b trials: BE VIVID, BE READY, BE SURE, their ongoing open-label extension (OLE) BE BRIGHT, and BE RADIANT (including its double-blinded treatment period and the first year of its OLE).
Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients.
Front Med (Lausanne)
November 2024
Department of Dermatology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Background: Upadacitinib, a specific JAK1 inhibitor, has minimal effect on other JAK subtypes. It influences the inflammatory process in various ways. Upadacitinib has been approved for conditions such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis in various countries.
View Article and Find Full Text PDFLong-Term Surgical Success in Treating Vohwinkel Syndrome: A Case Report.
JBJS Case Connect
October 2024
Department of Orthopaedic Surgery, Atrium Health Musculoskeletal Institute-Carolinas Medical Center, Charlotte, North Carolina.
Case: Vohwinkel syndrome is a rare, inherited condition marked by defective keratinization. The disorder may feature digital constriction bands (pseudoainhum) which can lead to autoamputation. Surgical excision is the only treatment of pseudoainhum; however, it is fraught with recurrence.
View Article and Find Full Text PDFCase report: Novel p.Val306Met missense mutation in in a case of Olmsted syndrome accompanied by squamous cell carcinoma.
Front Oncol
October 2024
Department of Dermatology, The First Affiliated Hospital of Huzhou University, Huzhou, China.
Article Synopsis
- A new case of OS was identified due to an unprecedented mutation in the associated gene, presenting with significant skin issues and leading to cancer on the foot.
- This discovery highlights the broad range of symptoms related to the gene's mutations and emphasizes the importance of continuous monitoring for affected individuals.
Efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study.
Int Immunopharmacol
December 2024
Department of Dermatology, Peking University People's Hospital, Beijing 100044, China. Electronic address:
Article Synopsis
- A two-year retrospective study involving 258 patients evaluated the long-term efficacy and safety of ixekizumab for treating difficult psoriasis.
- At one year, significant improvements were noted, with 92% of patients reaching PASI 75 and sustained efficacy at two years.
- Common side effects included local injection reactions and allergies, but there were no major concerns regarding latent infections or metabolic issues.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!